149 related articles for article (PubMed ID: 33302634)
1. Systematic analysis reveals a lncRNA-miRNA-mRNA network associated with dasatinib resistance in chronic myeloid leukemia.
Luo J; Gao Y; Lin X; Guan X
Ann Palliat Med; 2021 Feb; 10(2):1727-1738. PubMed ID: 33302634
[TBL] [Abstract][Full Text] [Related]
2. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
[TBL] [Abstract][Full Text] [Related]
3. LncRNA OIP5-AS1 Promotes the Autophagy-Related Imatinib Resistance in Chronic Myeloid Leukemia Cells by Regulating miR-30e-5p/ATG12 Axis.
Dai H; Wang J; Huang Z; Zhang H; Wang X; Li Q; Feng W
Technol Cancer Res Treat; 2021; 20():15330338211052150. PubMed ID: 34723728
[No Abstract] [Full Text] [Related]
4. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
8. Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis.
Kayabasi C; Caner A; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Asik A; Mutlu Z; Caliskan Kurt C; Goker Bagca B; Biray Avci C; Sahin F; Saydam G; Gunduz C
Med Oncol; 2022 Jan; 39(3):29. PubMed ID: 35059859
[TBL] [Abstract][Full Text] [Related]
9. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.
Guo G; Kang Q; Zhu X; Chen Q; Wang X; Chen Y; Ouyang J; Zhang L; Tan H; Chen R; Huang S; Chen JL
Oncogene; 2015 Apr; 34(14):1768-79. PubMed ID: 24837367
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Inoue A; Kobayashi CI; Shinohara H; Miyamoto K; Yamauchi N; Yuda J; Akao Y; Minami Y
Int J Hematol; 2018 Oct; 108(4):365-370. PubMed ID: 30155588
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
Morita K; Kantarjian HM; Sasaki K; Issa GC; Jain N; Konopleva M; Short NJ; Takahashi K; DiNardo CD; Kadia TM; Garcia-Manero G; Daver N; Montalban Bravo G; Cortes JE; Ravandi F; Jabbour E
Cancer; 2021 Aug; 127(15):2641-2647. PubMed ID: 33823073
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Copland M; Hamilton A; Elrick LJ; Baird JW; Allan EK; Jordanides N; Barow M; Mountford JC; Holyoake TL
Blood; 2006 Jun; 107(11):4532-9. PubMed ID: 16469872
[TBL] [Abstract][Full Text] [Related]
15. Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.
Deng Q; Wang E; Wu X; Cheng Q; Liu J; Li X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 45(7):874-880. PubMed ID: 32879093
[TBL] [Abstract][Full Text] [Related]
16. miRNAs in chronic myeloid leukemia: small molecules, essential function.
Litwińska Z; Machaliński B
Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267
[TBL] [Abstract][Full Text] [Related]
17. miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2.
Pan B; Yang J; Wang X; Xu K; Ikezoe T
Exp Hematol; 2018 Dec; 68():80-88.e2. PubMed ID: 30195077
[TBL] [Abstract][Full Text] [Related]
18. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
20. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
